A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

2023-507195-43-00 Protocol MP-101-02 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 1 Jul 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol MP-101-02

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 40
Countries 1
Sites 1

Amyotrophic Lateral Sclerosis (ALS)

Key facts

Sponsor
Mitochon Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
1 Jul 2024 → ongoing
Decision date (initial)
2023-11-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Amyotrophic Lateral Sclerosis (ALS)

VersionLevelCodeTermSystem organ class
21.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Mitochon Pharmaceuticals Inc.

Sponsor organisation
Mitochon Pharmaceuticals Inc.
Address
970 Cross Lane
City
Blue Bell
Postcode
19422-1574
Country
United States

Scientific contact point

Organisation
Mitochon Pharmaceuticals Inc.
Contact name
Chief Scientific Officer (CSO)

Public contact point

Organisation
Mitochon Pharmaceuticals Inc.
Contact name
Chief Scientific Officer (CSO)

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ongoing, recruiting 40 1
Rest of world 0

Investigational sites

Hungary

1 site · Ongoing, recruiting
CRU Hungary Kft.
Early Phase Unit, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2024-07-01 2024-07-02

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-01 Hungary Acceptable
2023-11-21
2023-11-28
2 SUBSTANTIAL MODIFICATION SM-1 2024-04-30 Hungary Acceptable
2024-05-23
2024-06-13
3 SUBSTANTIAL MODIFICATION SM-2 2024-09-04 Hungary Acceptable
2024-09-24
2024-09-30
4 SUBSTANTIAL MODIFICATION SM-3 2025-05-29 Hungary Acceptable
2025-07-28
2025-08-01